AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Baculoviral IAP repeat-containing protein 3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q13489

UPID:

BIRC3_HUMAN

Alternative names:

Apoptosis inhibitor 2; Cellular inhibitor of apoptosis 2; IAP homolog C; Inhibitor of apoptosis protein 1; RING finger protein 49; RING-type E3 ubiquitin transferase BIRC3; TNFR2-TRAF-signaling complex protein 1

Alternative UPACC:

Q13489; Q16628; Q9HC27; Q9UP46

Background:

Baculoviral IAP repeat-containing protein 3, known by names such as Apoptosis inhibitor 2 and Cellular inhibitor of apoptosis 2, plays a pivotal role in cellular processes. It regulates caspases, apoptosis, inflammatory signaling, immunity, cell proliferation, invasion, and metastasis. As an E3 ubiquitin-protein ligase, it modulates NF-kappa-B signaling, enhancing the canonical pathway while suppressing the non-canonical one. Its targets include RIPK1, CASP3, and TRAF1, crucial for innate immune signaling and preventing spontaneous ripoptosome formation, which can kill cancer cells.

Therapeutic significance:

Understanding the role of Baculoviral IAP repeat-containing protein 3 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.